Efficacy of Bortezomib-containing PAD, PCD and VRD Regimens in the Treatment of Newly-treated Multiple Myeloma and Its Impact on Cellular Immune Indexes and Safety

TAO Zhong; ZHU Xi-jun; LIU Ying-bin

doi:10.3969/j.issn.1002-3429.2022.05.011

Home>Articles>Efficacy of Bortezomib-containing PAD, PCD and VRD Regimens in the Treatment of Newly-treated Multiple Myeloma and Its Impact on Cellular Immune Indexes and Safety

DOI: 10.3969/j.issn.1002-3429.2022.05.011

Efficacy of Bortezomib-containing PAD, PCD and VRD Regimens in the Treatment of Newly-treated Multiple Myeloma and Its Impact on Cellular Immune Indexes and Safety

TAO Zhong

ZHU Xi-jun

LIU Ying-bin

Machine-generated Keywords：

Publication Date：2022-05-22

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：4( 35-38 )

Clinical Misdiagnosis & Mistherapy

ISTIC

ISSN：1002-3429

Year, Vol.(Issue)：2022,35(5)